ACELRX PHARMACEUTICALS INC's ticker is ACRX and the CUSIP is 00444T100. A total of 67 filers reported holding ACELRX PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 2.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $77,000 | +13.2% | 20,000 | 0.0% | 0.01% | +9.1% |
| Q2 2018 | $68,000 | -46.0% | 20,000 | -66.7% | 0.01% | -50.0% |
| Q1 2018 | $126,000 | -11.3% | 60,000 | -14.3% | 0.02% | -12.0% |
| Q4 2017 | $142,000 | -56.3% | 70,000 | -0.9% | 0.02% | -57.6% |
| Q3 2017 | $325,000 | +113.8% | 70,660 | 0.0% | 0.06% | +103.4% |
| Q2 2017 | $152,000 | -40.2% | 70,660 | -12.4% | 0.03% | -42.0% |
| Q1 2017 | $254,000 | +21.0% | 80,660 | 0.0% | 0.05% | +19.0% |
| Q4 2016 | $210,000 | -33.1% | 80,660 | 0.0% | 0.04% | -34.4% |
| Q3 2016 | $314,000 | +44.7% | 80,660 | 0.0% | 0.06% | +39.1% |
| Q2 2016 | $217,000 | -12.5% | 80,660 | 0.0% | 0.05% | -16.4% |
| Q1 2016 | $248,000 | -8.8% | 80,660 | +14.2% | 0.06% | -17.9% |
| Q4 2015 | $272,000 | +25.9% | 70,660 | 0.0% | 0.07% | +15.5% |
| Q3 2015 | $216,000 | -28.0% | 70,660 | 0.0% | 0.06% | -24.7% |
| Q2 2015 | $300,000 | +9.9% | 70,660 | 0.0% | 0.08% | +11.6% |
| Q1 2015 | $273,000 | -70.1% | 70,660 | -47.9% | 0.07% | -71.8% |
| Q4 2014 | $913,000 | – | 135,660 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Values First Advisors, Inc. | 250,110 | $528,000 | 0.51% |
| XTX MARKETS LLC | 12,925 | $27,000 | 0.19% |
| Cornerstone Capital, Inc. | 491,560 | $1,037,000 | 0.15% |
| Aristides Capital LLC | 64,482 | $136,000 | 0.10% |
| LINCOLN CAPITAL CORP | 57,000 | $120,000 | 0.09% |
| HighVista Strategies LLC | 41,400 | $87,000 | 0.07% |
| Ahrens Investment Partners LLC | 61,500 | $130,000 | 0.05% |
| J Arnold Wealth Management Co | 18,000 | $38,000 | 0.05% |
| GSA CAPITAL PARTNERS LLP | 114,437 | $241,000 | 0.03% |
| Avidian Wealth Solutions, LLC | 63,000 | $133,000 | 0.02% |